Ar­riVent out­lines plans for $135M IPO in sec­ond biotech list­ing of 2024

Ar­riVent Bio­phar­ma, a Penn­syl­va­nia drug­mak­er de­vel­op­ing a Chi­na-ap­proved can­cer treat­ment for the US and oth­er ge­o­gra­phies, plans to raise net pro­ceeds of about $135 mil­lion …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER